 Home > Active Ingredient News > Blood System > HAEMATOLOGICA: Excellent survival with rituximab combined with LMB-based chemotherapy in children and adolescents with primary mediastinal large B-cell lymphoma

HAEMATOLOGICA: Excellent survival with rituximab combined with LMB-based chemotherapy in children and adolescents with primary mediastinal large B-cell lymphoma

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

5 1 2 mm

1 8 thread

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Primary mediastinal large B-cell lymphoma (PMLBL) is a rare disease that primarily affects adolescents and young adults
.

More recently, an international phase 2 trial of dose-adjusted etoposide, doxorubicin, and cyclophosphamide in combination with vincristine and prednisone plus rituximab (DA-EPOCH-R) in pediatric patients failed to yield positive results.

A French prospective LMB2001 trial included all patients younger than 18 years of age with mature B-cell lymphoma treated at French centers
.

For patients with PMLBL, treatment consists of 4 to 8 cycles of Lymphomes Malins B (LMB)-based chemotherapy without radiation

Figure 1: KaplanMeier estimates of overall survival and event-free survival
.

EFS, event-free survival; OS, overall survival The vertical line represents the Rothman 95% confidence interval

Figure 2: KaplanMeier estimates of event-free survival and overall survival based on rituximab dosing panel A, representing event-free survival
.

Panel B represents overall survival

Figure 2: KaplanMeier estimates of event-free survival and overall survival based on rituximab dosing panel A, representing event-free survival

The 5-year EFS was 81.

Only 1/21 of patients receiving rituximab and LMB-based chemotherapy experienced local early treatment failure, but second-line chemotherapy and radiation prolonged complete remission

Original source:

Original credit: Dourthe ME, Phulpin A, Auperin A, Bosq J, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Leblanc T, Leruste A, Paillard C, Rigaud C, Simonin M, Patte C, Minard- Colin V.
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study.
Haematologica; https://doi.
org/10.
3324/haematol.
2021.
280257 [Early view] .

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Atipamezole hydrochloride 104075-48-1 reduce sedation lower blood pressure

CAS No.: 104075-48-1

Pharm grade

$1/G EXW

Pharma Grade Fasudil hydrochloride CAS:105628-07-7 for High Purity

CAS No.: 105628-07-7

Pharmacy Grade;

$4.8-5.5/G FOB

Nutritional Supplement Chemicals Whey Protein CAS:91082-88-1/84082-51-9 for Food Grdade

CAS No.: 84082-51-9

Pharmacy Grade;

$40-50/KG FOB

Hot Tags

jobs united states(236)

united states jobs(223)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

ups united states(221)

announcements today(81)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.